HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 09, September 2019 – Healthy Ageing — How Science is chipping in       » Officials in China make progress in development of new drugs       » The Science of Healthy Ageing       » Thailand Medtech landscape - Customer to Innovator       » China-Thailand Joint Research Institute on Medicine Launched in Bangkok      
NEWS CRUNCH
Australian cancer specialists may hold key to next advancement in ovarian cancer treatment
The drug, Cantrixil, has shown evidence in the laboratory of being able to target and kill cancer stem cells responsible for relapse. It is being developed as a first line treatment in combination with IV chemo (to prevent relapse), and to treat women who have recurrent ovarian cancer and have become resistant to chemo.

Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy.

Associate Professor Jim Coward, an oncologist at Icon Cancer Care in South Brisbane, is leading the first clinical trial of Cantrixil, a locally developed molecule by biotech Novogen that could enable intraperitoneal (IP) chemotherapy to again become a viable treatment option in patients where it has become ineffective due to resistance.[1]

Flinders Medical Centre in South Australia and Westmead Hospital in Sydney are also participating, along with leading US hospitals Peggy and Charles Stephenson Cancer Centre, and Mary Crowley Cancer Research Centre.

The Phase 1 trial, which is designed to understand the safety profile of Cantrixil in human subjects and establish a Maximum Tolerated Dose (MTD) for the drug, commenced in December 2016 and preliminary results are expected as early as next year.

Ovarian cancer is the eighth most common cancer in women, and the sixth most common cause of cancer death for women in Australia.[2] The Australian Institute of Health and Welfare estimates that in 2017, 1580 new cases will be diagnosed and 1047 women will die from ovarian cancer.[3]

"We've seen massive developments in other types of cancer but ovarian cancer has remained a challenge and, despite it being an unforgiving disease for women, treatment options have fallen behind as money and research are focused elsewhere," Associate Professor Coward said.

"The survival rate for ovarian cancer is poor because of the high rate of relapse after standard-of-care treatment and the late stage at which the disease tends to be diagnosed. The vast majority of patients who relapse will eventually become resistant to chemotherapy, so it's imperative that we have a bigger portfolio of treatment options."

Recurrent, chemo-resistant ovarian cancer is thought to be due to a subgroup of slow-growing, drug resistant cancer cells with stem-like properties and a high capacity for tumour repair. These are often referred to as tumour-initiating cells or 'cancer stem cells'.[1]

"Cantrixil could be a compelling treatment for patients with recurrent ovarian cancer because it has shown evidence in the laboratory of being able to target and kill the sub-population of cancer stem cells or tumour-initiating cells that are responsible for cancers originating, metastasising and relapsing," Associate Professor Coward said.

"This new treatment is being developed as an IP chemotherapy that we hope will be used as both first line and recurrent therapies in combination with carboplatin administered intravenously (IV) for epithelial ovarian cancer, which is the most common form of ovarian cancer, comprising 90% of cases[2].

"We know that if a surgeon is able to remove all of the visible disease during an ovarian cancer patient's initial operation, combination IP and IV therapy is associated with vastly superior outcomes."

Novogen CEO and Executive Director Dr James Garner said: "We are pleased with the progress to date in the phase 1 study of Cantrixil. Novogen is fortunate to be working with highly-experienced clinicians at leading trial centres. We remain excited by the potential for Cantrixil to become an important addition to the treatment landscape in ovarian cancer and are grateful to those patients who are participating in the study."

Source: Novogen Limited

References:

  1. Wasif Saif M, Heaton A, Lilischkis K, Garner J, Brown D.M, Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX E 002 1), Journal of Cancer Chemotherapy and Pharmacology, 2016, DOI 10.1007/s00280-016-3224-2 [ONLINE] https://nrt.irmau.com/irm/PDF/1583_0/JournalofCancerChemotherapyandPharmacology
  2. Cancer Council Australia [online] https://www.cancer.org.au/about-cancer/types-of-cancer/ovarian-cancer.html [accessed] 17 August 2017.
  3. Australian Institute of Health and Welfare 2017. Cancer in Australia 2017. Cancer series no.100. Cat. no. CAN 100. Canberra: AIHW
NEWS CRUNCH  
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
news Medial Fair Thailand opened on 11th September 2019 with a focus on future-proofing Thailand's healthcare industry to meet the challenges and opportunities of the next decade
news Biofuel Producers and Users to Convene in Singapore for Global Biofuels Summit
news Philip Morris International opens artificial intelligence competition to develop improved strategies for medical diagnosis
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy